Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

New Evidence With BTK Inhibitor Therapy in CLL and MCL From the Pan Pacific Lymphoma Conference 2022

Source: A Global Perspective on Emerging BTK Inhibitor Therapy Data for Relapsed/Refractory CLL and MCL in 2022*
2022 ASCO Annual Meeting, June 3-7, 2022, in Chicago, Illinois, USA; EHA 2022 Congress, June 9-12, 2022, in Vienna, Austria; 2022 Pan Pacific Lymphoma Conference, July 18-22, 2022, in Koloa, Hawaii, USA; ESMO 2022 Annual Congress, September 9-13, 2022, in Paris, France; 2022 SOHO Annual Meeting, September 28 - October 1, 2022, in Houston, Texas, USA
Gain insight from expert perspectives on key studies from the Pan Pacific Lymphoma Conference 2022 covering BTK inhibition in chronic lymphocytic leukemia and mantle cell lymphoma and the potential implications for clinical practice.
Matthew S. Davids, MD, MMSc
Julie M. Vose, MD, MBA
Released: August 30, 2022

In this episode, Julie M. Vose, MD, MBA, and Matthew S. Davids, MD, MMSc, discuss their choices of recent important trials presented at the Pan Pacific Lymphoma Conference 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of:

  • BRUIN (CLL/small lymphocytic lymphoma [SLL]): phase I/II study of pirtobrutinib for previously treated CLL (including previous BTK inhibitor)
  • SEQUOIA: phase III study evaluating cohort 1 of zanubrutinib vs bendamustine/rituximab in untreated CLL/SLL without del(17p)
  • MAJIC: phase III trial in progress of acalabrutinib + venetoclax vs venetoclax + obinutuzumab in previously untreated CLL
  • BRUIN (MCL): phase I/II study of pirtobrutinib for previously treated MCL (including previous BTK inhibitor)
  • BRUIN MCL-321: phase III trial in progress of pirtobrutinib vs investigator’s choice acalabrutinib, ibrutinib, or zanubrutinib in previously treated, BTK inhibitor–naive MCL
  • BRIDGE: series case report from phase II study evaluating zanubrutinib-based induction and maintenance in young patients with MCL

Information on this Educational Activity

Faculty

Matthew S. Davids, MD, MMSc

Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Matthew S. Davids, MD, MMSc: consultant: AbbVie, Adaptive Biotechnologies, Ascentage, AstraZeneca, BeiGene, Bristol-Myers Squibb, Genentech, Janssen, Lilly, Merck, Ono Pharmaceuticals, Research to Practice, Takeda, TG Therapeutics, Verastem, Zentalis; researcher: AstraZeneca, Genentech, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics, Verastem.
Julie M. Vose, MD, MBA

Chief, Division of Oncology and Hematology
Neumann M. and Mildred E. Harris Professor
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Julie M. Vose, MD, MBA: consultant/advisor: AbbVie, AstraZeneca, Caribou, Daiichi Sankyo, Genentech, Lilly, MEI Pharma, MorphoSys, Pharmacyclics

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC.
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings